DK3250691T5 - Hybride crispr-dna/rna-polynucleotider og fremgangsmåder til deres anvendelse - Google Patents

Hybride crispr-dna/rna-polynucleotider og fremgangsmåder til deres anvendelse Download PDF

Info

Publication number
DK3250691T5
DK3250691T5 DK16704978.2T DK16704978T DK3250691T5 DK 3250691 T5 DK3250691 T5 DK 3250691T5 DK 16704978 T DK16704978 T DK 16704978T DK 3250691 T5 DK3250691 T5 DK 3250691T5
Authority
DK
Denmark
Prior art keywords
methods
rna polynucleotides
crispr dna
hybrid
hybrid crispr
Prior art date
Application number
DK16704978.2T
Other languages
Danish (da)
English (en)
Other versions
DK3250691T3 (da
Inventor
Andrew P May
Paul D Donohoue
Original Assignee
Caribou Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caribou Biosciences Inc filed Critical Caribou Biosciences Inc
Publication of DK3250691T3 publication Critical patent/DK3250691T3/da
Application granted granted Critical
Publication of DK3250691T5 publication Critical patent/DK3250691T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK16704978.2T 2015-01-28 2016-01-27 Hybride crispr-dna/rna-polynucleotider og fremgangsmåder til deres anvendelse DK3250691T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562108931P 2015-01-28 2015-01-28
US201562251548P 2015-11-05 2015-11-05
PCT/US2016/015145 WO2016123230A1 (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use

Publications (2)

Publication Number Publication Date
DK3250691T3 DK3250691T3 (da) 2023-09-18
DK3250691T5 true DK3250691T5 (da) 2024-10-07

Family

ID=55361965

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16704978.2T DK3250691T5 (da) 2015-01-28 2016-01-27 Hybride crispr-dna/rna-polynucleotider og fremgangsmåder til deres anvendelse

Country Status (27)

Country Link
US (11) US9650617B2 (enExample)
EP (2) EP3250691B9 (enExample)
JP (2) JP6835726B2 (enExample)
KR (4) KR102319192B1 (enExample)
CN (2) CN111518811A (enExample)
AU (3) AU2016211517B2 (enExample)
BR (1) BR112017016080B1 (enExample)
CA (2) CA2975166C (enExample)
DK (1) DK3250691T5 (enExample)
ES (1) ES2955957T3 (enExample)
FI (1) FI3250691T3 (enExample)
GB (1) GB2550745A (enExample)
HR (1) HRP20231022T1 (enExample)
HU (1) HUE063813T2 (enExample)
IL (4) IL288263B (enExample)
LT (1) LT3250691T (enExample)
MX (2) MX2017009506A (enExample)
NZ (1) NZ733702A (enExample)
PL (1) PL3250691T3 (enExample)
PT (1) PT3250691T (enExample)
RS (1) RS64527B1 (enExample)
RU (1) RU2713328C2 (enExample)
SG (3) SG10201906513WA (enExample)
SI (1) SI3250691T1 (enExample)
SM (1) SMT202300341T1 (enExample)
WO (1) WO2016123230A1 (enExample)
ZA (2) ZA201705174B (enExample)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR085533A1 (es) 2011-03-23 2013-10-09 Pioneer Hi Bred Int Metodos de produccion de un locus de rasgos transgenicos complejo
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
CN106133138A (zh) 2013-08-22 2016-11-16 先锋国际良种公司 使用引导多核苷酸/cas内切核酸酶系统的基因组修饰及其使用方法
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
BR112017003757A2 (pt) 2014-09-12 2017-12-26 Du Pont ?plantas de milho, partes de planta de milho ou sementes de milho?
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
AU2016211517B2 (en) 2015-01-28 2021-05-13 Caribou Biosciences, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
BR112017017260A2 (pt) 2015-03-27 2018-04-17 Du Pont construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
US20160362667A1 (en) * 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
US11279928B2 (en) 2015-06-29 2022-03-22 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
JP2018519811A (ja) 2015-06-29 2018-07-26 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ｃｒｉｓｐｒ ｒｎａ及び修飾単一ｃｒｉｓｐｒ ｒｎａならびにその使用
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
EP3350327B1 (en) 2015-10-23 2018-09-26 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3564371B1 (en) * 2015-12-04 2020-05-27 Caribou Biosciences, Inc. Engineered nucleic-acid targeting nucleic acids
AU2016365720B2 (en) 2015-12-07 2020-11-26 Arc Bio, Llc Methods and compositions for the making and using of guide nucleic acids
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
JP6821598B2 (ja) 2015-12-07 2021-01-27 ザイマージェン インコーポレイテッド Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ ｇｌｕｔａｍｉｃｕｍ由来のプロモーター
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
CN106244591A (zh) * 2016-08-23 2016-12-21 苏州吉玛基因股份有限公司 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用
JP2019517261A (ja) 2016-06-01 2019-06-24 カーヴェーエス ザート ソシエタス・ヨーロピアＫｗｓ Ｓａａｔ Ｓｅ ゲノム操作のためのハイブリッド核酸配列
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
EP3478833A4 (en) 2016-06-30 2019-10-02 Zymergen, Inc. METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE
US10544411B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
US11845929B2 (en) * 2016-07-08 2023-12-19 Ohio State Innovation Foundation Modified nucleic acids, hybrid guide RNAs, and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018031950A1 (en) 2016-08-12 2018-02-15 Caribou Biosciences, Inc. Protein engineering methods
JP7050215B2 (ja) * 2016-08-19 2022-04-08 ツールゲン インコーポレイテッド 人工的に操作された血管新生調節系
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3034931A1 (en) 2016-09-23 2018-03-29 Board Of Trustees Of Southern Illinois University Tuning crispr/cas9 activity with chemically modified nucleotide substitutions
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
WO2018068053A2 (en) 2016-10-07 2018-04-12 Integrated Dna Technologies, Inc. S. pyogenes cas9 mutant genes and polypeptides encoded by same
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US20180282722A1 (en) * 2016-11-21 2018-10-04 Massachusetts Institute Of Technology Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
CA3044101A1 (en) 2016-11-22 2018-05-31 Integrated Dna Technologies, Inc. Crispr/cpf1 systems and methods
US9816093B1 (en) 2016-12-06 2017-11-14 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
WO2018111947A1 (en) 2016-12-12 2018-06-21 Integrated Dna Technologies, Inc. Genome editing enhancement
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
AU2017388379A1 (en) * 2016-12-28 2019-06-06 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and uses thereof
WO2018129368A2 (en) 2017-01-06 2018-07-12 Editas Medicine, Inc. Methods of assessing nuclease cleavage
EA201991809A1 (ru) * 2017-01-30 2020-02-05 КВС ЗААТ СЕ & КО. КГаА Сцепление матрицы для репарации с эндонуклеазами для геномной инженерии
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
EP3526324B1 (en) 2017-03-28 2021-08-25 Locanabio, Inc. Crispr-associated (cas) protein
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN108977442B (zh) * 2017-06-05 2023-01-06 广州市锐博生物科技有限公司 用于dna编辑的系统及其应用
CA3102054A1 (en) 2017-06-05 2018-12-13 Fred Hutchinson Cancer Research Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
ES2875579T3 (es) 2017-06-06 2021-11-10 Zymergen Inc Plataforma de ingeniería genómica de HTP para mejorar Escherichia coli
JP7227162B2 (ja) 2017-06-06 2023-02-21 ザイマージェン インコーポレイテッド 真菌株を改良するためのｈｔｐゲノム操作プラットフォーム
EP3635114B1 (en) * 2017-06-07 2024-11-06 Arc Bio, LLC Creation and use of guide nucleic acids
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
KR102634727B1 (ko) 2017-06-14 2024-02-07 위스콘신 얼럼나이 리서어치 화운데이션 변형된 가이드 rna, crispr-리보뉴클레오프로테인 복합체 및 사용 방법
CN107488710B (zh) 2017-07-14 2020-09-22 上海吐露港生物科技有限公司 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11584955B2 (en) * 2017-07-14 2023-02-21 Shanghai Tolo Biotechnology Company Limited Application of Cas protein, method for detecting target nucleic acid molecule and kit
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
IL310452A (en) 2017-08-09 2024-03-01 Ricetec Inc Preparations and methods for genome modification
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
EP3676378A4 (en) 2017-08-31 2021-06-09 The New York Genome Center PROCEDURES AND COMPOSITIONS USING CRIMP-CPF1 AND PAIRED GUIDE-CRISPR-RNA FOR PROGRAMMABLE GENOMIC DELETIONS
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
JP7423520B2 (ja) 2017-11-16 2024-01-29 アストラゼネカ・アクチエボラーグ Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
WO2019113132A1 (en) 2017-12-05 2019-06-13 Caribou Biosciences, Inc. Modified lymphocytes
CN120118207A (zh) 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US20190233816A1 (en) * 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US20210093679A1 (en) 2018-02-05 2021-04-01 Novome Biotechnologies, Inc. Engineered gut microbes and uses thereof
KR20200124702A (ko) 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
WO2019173248A1 (en) 2018-03-07 2019-09-12 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
AU2019255789B2 (en) 2018-04-19 2025-11-20 The Regents Of The University Of California Compositions and methods for gene editing
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
JP6965466B2 (ja) * 2018-06-13 2021-11-10 カリブー・バイオサイエンシーズ・インコーポレイテッド 操作されたカスケード構成要素およびカスケード複合体
US10227576B1 (en) 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US12227776B2 (en) 2018-06-13 2025-02-18 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
EP3847251A1 (en) 2018-09-07 2021-07-14 Astrazeneca AB Compositions and methods for improved nucleases
ES2927220T3 (es) 2018-10-01 2022-11-03 Caribou Biosciences Inc Composiciones y procedimientos de módulos suicidas
KR102126573B1 (ko) 2018-10-18 2020-06-26 대한민국 CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
EP3874037A4 (en) * 2018-10-31 2021-12-15 Zymergen, Inc. DETERMINIST MULTIPLEXED SET OF DNA LIBRARIES
US11739320B2 (en) 2018-11-05 2023-08-29 Wisconsin Alumni Research Foundation Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
CN113166744B (zh) 2018-12-14 2025-02-07 先锋国际良种公司 用于基因组编辑的新颖crispr-cas系统
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020210884A1 (en) * 2019-01-25 2021-08-12 Synthego Corporation Systems and methods for modulating CRISPR activity
US20220290120A1 (en) 2019-02-25 2022-09-15 Novome Biotechnologies, Inc. Plasmids for gene editing
WO2020185590A1 (en) 2019-03-08 2020-09-17 Zymergen Inc. Iterative genome editing in microbes
WO2020185584A1 (en) 2019-03-08 2020-09-17 Zymergen Inc. Pooled genome editing in microbes
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US10982187B2 (en) 2019-03-26 2021-04-20 Genus Plc Bos taurus variety ‘HO840003150607238’ and methods of use thereof
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
GB201907733D0 (en) * 2019-05-31 2019-07-17 Governing Council Of The Univ Of Toronto Methods and compositions for multiplex gene editing
US10975351B2 (en) 2019-06-17 2021-04-13 Abs Global, Inc. Bos taurus variety ‘JE840003146074527’ and methods of use therof
CN114729381A (zh) * 2019-09-05 2022-07-08 本森希尔股份有限公司 修饰基因组的组合物和方法
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021099996A1 (en) 2019-11-19 2021-05-27 Benson Hill, Inc. Anti-bacterial crispr compositions and methods
WO2021119006A1 (en) 2019-12-09 2021-06-17 Caribou Biosciences, Inc. Crispr abasic restricted nucleotides and crispr accuracy via analogs
AU2021216418A1 (en) * 2020-02-05 2022-09-01 Danmarks Tekniske Universitet Compositions and methods for targeting, editing or modifying human genes
US20230087228A1 (en) * 2020-02-24 2023-03-23 The Broad Institute, Inc. Novel type iv and type i crispr-cas systems and methods of use thereof
CN115427566A (zh) 2020-04-08 2022-12-02 阿斯利康(瑞典)有限公司 用于改善的位点特异性修饰的组合物和方法
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US20210388348A1 (en) * 2020-05-12 2021-12-16 University Of Massachusetts Modified guide rnas for crispr genome editing
CA3198905A1 (en) * 2020-10-19 2022-04-28 Caribou Biosciences, Inc. Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same
CN112301162B (zh) * 2020-10-22 2023-09-22 清华-伯克利深圳学院筹备办公室 同时检测dna病毒和rna病毒的病毒核酸检测方法
AU2022227650A1 (en) * 2021-02-25 2023-10-12 Celyntra Therapeutics Sa Compositions and methods for targeting, editing, or modifying genes
US20240182890A1 (en) 2021-04-07 2024-06-06 Astrazeneca Ab Compositions and methods for site-specific modification
GB2702733A (en) * 2021-09-22 2026-06-24 Verve Therapeutics Inc Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease
JP2024536135A (ja) 2021-09-30 2024-10-04 アストラゼネカ・アクチエボラーグ ＣＲＩＳＰＲ／Ｃａｓ挿入の効率を増大させるための阻害剤の使用
WO2023076857A1 (en) 2021-10-26 2023-05-04 Caribou Biosciences, Inc. Exonuclease-coupled real-time endonuclease activity assay
CN118355129A (zh) * 2021-12-07 2024-07-16 卡里布生物科学公司 捕获crispr核酸内切酶切割产物的方法
CN118974256A (zh) * 2022-03-29 2024-11-15 锐正基因(苏州)有限公司 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
US20250325698A1 (en) * 2022-04-13 2025-10-23 Caribou Biosciences, Inc. Therapeutic applications of crispr type v systems
WO2023224327A1 (ko) * 2022-05-20 2023-11-23 한국생명공학연구원 오토라이신을 활용한 미세조류의 유전자 교정 효율을 증대시키기 위한 시스템 및 방법
WO2023230529A1 (en) 2022-05-26 2023-11-30 Caribou Biosciences, Inc. Cytokine-receptor fusions for immune cell stimulation
CN119546326A (zh) 2022-06-06 2025-02-28 卡里布生物科学公司 用经工程化的免疫细胞治疗自身免疫性疾病
EP4578945A4 (en) 2022-08-26 2025-12-17 Guangzhou Reforgene Medicine Co Ltd CRISPR-CAS13 SYSTEM AND ITS USE
AU2023353989A1 (en) 2022-09-30 2025-02-27 Caribou Biosciences, Inc. Anti-ror1 chimeric antigen receptors (cars), cells expressing the cars and related methods
EP4584283A1 (en) 2022-11-14 2025-07-16 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
EP4414452A1 (en) * 2023-02-13 2024-08-14 Universidad de Granada Dual-guide rna composition for executing a single-guide rna crispr-associated system
CN121127605A (zh) 2023-03-29 2025-12-12 阿斯利康(瑞典)有限公司 使用抑制剂来提高CRISPR/Cas插入的效率
WO2024228989A1 (en) 2023-05-01 2024-11-07 Caribou Biosciences, Inc. Treatment of autoimmune diseases with bcma-targeting engineered immune cells
JP2026523341A (ja) 2023-05-15 2026-07-14 エヌクロマ・バイオ，インコーポレーテッド Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法
WO2025006880A1 (en) 2023-06-29 2025-01-02 Caribou Biosciences, Inc. Diagnostic and therapeutic methods for use with ror1 antagonists
EP4750913A1 (en) 2023-07-26 2026-06-03 Caribou Biosciences, Inc. In vitro validation methods for cd19-targeting cell therapies
CN121816418A (zh) 2023-08-02 2026-04-07 广州瑞风生物科技股份有限公司 基因编辑系统及其应用
CN119614679B (zh) * 2023-09-14 2026-07-28 厦门大学 一款通用型核酸检测平台
WO2025064930A1 (en) * 2023-09-20 2025-03-27 Emory University Nucleic acid hairpin based triggered hydrogels and uses thereof
WO2025117745A1 (en) 2023-12-01 2025-06-05 Caribou Biosciences, Inc. Methods and compositions for improving precision of endonuclease-mediated genome editing
WO2025193609A1 (en) 2024-03-11 2025-09-18 Caribou Biosciences, Inc. Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells
WO2025193386A1 (en) 2024-03-13 2025-09-18 Caribou Biosciences, Inc. Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors
WO2026050087A1 (en) 2024-08-27 2026-03-05 Caribou Biosciences, Inc. Real-time crispr endonuclease activity assay
US20260085302A1 (en) * 2024-09-20 2026-03-26 Confluence Genetics, Llc Compositions and methods for controlling plant pests
WO2026062583A2 (en) 2024-09-20 2026-03-26 Confluence Genetics, Llc Compositions and methods for modifying genomes
WO2026083309A1 (en) 2024-10-17 2026-04-23 Astrazeneca Ab Use of inhibitors or modulators of artemis in gene editing
WO2026136949A1 (en) 2024-12-19 2026-06-25 Caribou Biosciences, Inc. Cd19-targeting engineered immune cells and related methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US7256322B2 (en) 1999-10-01 2007-08-14 Pioneer Hi-Bred International, Inc. Wuschel (WUS) Gene Homologs
ATE420188T1 (de) 2004-02-02 2009-01-15 Pioneer Hi Bred Int Ap2-domäne-transkriptionsfaktor odp2 (ovule development protein 2) und verwendungsverfahren
MX2009009071A (es) * 2007-03-02 2009-09-24 Danisco Cultivos con resistencia mejorada a fagos.
CA2798703A1 (en) 2010-05-10 2011-11-17 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
CN116622704A (zh) 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
ES2749624T3 (es) 2013-03-14 2020-03-23 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
CN105408483A (zh) * 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
ES2777217T3 (es) * 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
CN106133138A (zh) * 2013-08-22 2016-11-16 先锋国际良种公司 使用引导多核苷酸/cas内切核酸酶系统的基因组修饰及其使用方法
EP3835419A1 (en) * 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
AU2016211517B2 (en) 2015-01-28 2021-05-13 Caribou Biosciences, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use

Also Published As

Publication number Publication date
SG11201705788TA (en) 2017-08-30
AU2023202056A1 (en) 2023-05-04
SG10201804715WA (en) 2018-07-30
KR20170126875A (ko) 2017-11-20
ZA201803945B (en) 2019-09-25
CA3060508C (en) 2023-08-29
IL253608A0 (en) 2017-09-28
LT3250691T (lt) 2023-09-11
IL288263B (en) 2022-07-01
US20230193324A1 (en) 2023-06-22
IL262042B (en) 2020-03-31
US20160362668A1 (en) 2016-12-15
AU2021202913B2 (en) 2023-02-16
EP3250691B1 (en) 2023-06-21
EP4257690A2 (en) 2023-10-11
KR20190112855A (ko) 2019-10-07
EP4257690A3 (en) 2024-03-27
US9580701B2 (en) 2017-02-28
IL288263A (en) 2022-01-01
US9771601B2 (en) 2017-09-26
US9650617B2 (en) 2017-05-16
RU2017130143A3 (enExample) 2019-07-17
FI3250691T3 (fi) 2023-08-24
US20170349915A1 (en) 2017-12-07
RU2713328C2 (ru) 2020-02-04
CN111518811A (zh) 2020-08-11
CA2975166C (en) 2020-01-14
EP3250691B9 (en) 2023-08-02
SMT202300341T1 (it) 2023-11-13
SI3250691T1 (sl) 2023-10-30
US20200056209A1 (en) 2020-02-20
KR102319192B1 (ko) 2021-10-28
ES2955957T3 (es) 2023-12-11
US11459588B2 (en) 2022-10-04
US12644138B2 (en) 2026-06-02
MX2024015281A (es) 2025-02-10
US20160215300A1 (en) 2016-07-28
WO2016123230A1 (en) 2016-08-04
US20170226534A1 (en) 2017-08-10
GB2550745A (en) 2017-11-29
SG10201906513WA (en) 2019-09-27
HRP20231022T1 (hr) 2023-12-08
JP2019162140A (ja) 2019-09-26
AU2023202056B2 (en) 2023-05-18
US20200354750A1 (en) 2020-11-12
US20210371883A1 (en) 2021-12-02
DK3250691T3 (da) 2023-09-18
KR20220159498A (ko) 2022-12-02
JP7038079B2 (ja) 2022-03-17
JP2018503386A (ja) 2018-02-08
US9688972B2 (en) 2017-06-27
IL253608B (en) 2019-02-28
NZ733702A (en) 2022-04-29
PL3250691T3 (pl) 2023-11-27
BR112017016080A2 (en) 2018-04-03
IL273147B (en) 2021-12-01
RU2017130143A (ru) 2019-02-28
RS64527B1 (sr) 2023-09-29
CA2975166A1 (en) 2016-08-04
HK1245839A1 (en) 2018-08-31
JP6835726B2 (ja) 2021-02-24
MX2017009506A (es) 2017-11-02
US20180142263A1 (en) 2018-05-24
AU2016211517B2 (en) 2021-05-13
US20170121694A1 (en) 2017-05-04
CA3060508A1 (en) 2016-08-04
AU2016211517A1 (en) 2017-08-03
IL262042A (en) 2018-11-29
ZA201705174B (en) 2018-12-19
HUE063813T2 (hu) 2024-02-28
IL273147A (en) 2020-04-30
US11236364B2 (en) 2022-02-01
AU2021202913A1 (en) 2021-06-03
US10519468B2 (en) 2019-12-31
US9868962B2 (en) 2018-01-16
CN107810270A (zh) 2018-03-16
US20250376700A1 (en) 2025-12-11
PT3250691T (pt) 2023-09-25
KR20190008998A (ko) 2019-01-25
BR112017016080B1 (pt) 2024-02-20
GB201712504D0 (en) 2017-09-20
EP3250691A1 (en) 2017-12-06
US10988781B2 (en) 2021-04-27

Similar Documents

Publication Publication Date Title
DK3250691T3 (da) Hybride crispr-dna/rna-polynucleotider og fremgangsmåder til deres anvendelse
IL262361B1 (en) Preparations and methods for cell programming using targeted nucleic acid nanocarriers
EP3313989C0 (en) MODIFIED CRISPR RNA AND MODIFIED SINGLE CRISPR RNA AND USES THEREOF
PL3604527T3 (pl) Zastosowanie programowalnych białek wiążących dna do wzmocnienia celowanej modyfikacji genomu
IL256905A (en) Methods for Amplifying Nucleic Acid Sequences
PT3325669T (pt) Composições e métodos de análise de rna
DK3115457T3 (da) Fremgangsmåde til modificering af genomsekvens til specifikt at konvertere nukleinsyrebaser af målrettet dna-sekvens og molekylært kompleks til anvendelse i samme
DK3310909T3 (da) Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet
SG11201605906UA (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
SG11201707663SA (en) Lyophilization of rna
PT3371314T (pt) Modificação genómica de células pluripotentes
BR112017008877A2 (pt) métodos e composições para sequenciamento de ácido nucleico-alvo
DK3265102T3 (da) Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling
GB201507115D0 (en) Nucleic Acid Construct
IL263870A (en) Improvements in or relating to nucleic acid amplification processes
DK3652314T3 (da) Nukleinsyreekstraktionsmaterialer og -fremgangsmåder
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
DK3350343T3 (da) Fremgangsmåder og sammensætninger til genommålberigelse og selektiv dna-sekventering
EP3346006A4 (en) METHOD FOR DNA AMPLIFICATION
DK3837970T3 (da) Herbicidtolerancegener og fremgangsmåder til anvendelse deraf
GB201805223D0 (en) Nucleic acid amplification
EP4209597C0 (en) NUCLEIC ACID SEQUENCING PROCESS
DK3227430T3 (da) Svampeværtsstammer, dna-konstruktioner og fremgangsmåder til anvendelse
DK3113793T3 (da) Dna-vektor og transformerede tumorcellevacciner
PT3408408T (pt) Amplificacao seletiva das regiqes do acido nucleico desejadas numa sequencia alvo